Sifang Optoelectronics makes strategic investment in Changhe Biotechnology
January 20, 2026
Source: drugdu
24
On January 16th, A strategic investment signing ceremony was held in Shanghai between Sifang Optoelectronics and Suzhou Changhe Biotechnology Co., Ltd. (hereinafter referred to as "Changhe Biotechnology") . Sifang Optoelectronics acquired 57.14% of Changhe Biotechnology's equity through a combination of capital transfer and capital increase using its own funds. This strategic integration with Changhe Biotechnology will allow the two companies to deeply integrate in areas such as product technology development, operational production, and sales channels, thereby leveraging Sifang Optoelectronics ' sensor technology...The company is expanding into more advanced biosafety testing instruments. Meanwhile, leveraging its expertise in core components within the sensor field, Sifang Optoelectronics will develop low-cost biosafety sensors for mass-market applications in home appliances, automobiles, and buildings.
https://finance.eastmoney.com/a/202601193622798315.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- 20-Valent Pneumococcal Vaccine Approved for Clinical Trials January 20, 2026
- ADC205 Tablets Received Approval for Drug Clinical Trial January 20, 2026
- Mingde Bio plans to acquire a 51% stake in Hunan Lanyi through capital increase and acquisition January 20, 2026
- accelerating the transition of CLL treatment into a “chemotherapy-free era”. January 20, 2026
- Clinical trials successful, development terminated. January 20, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
